Impairment of Methotrexate Transport Is Common in Osteosarcoma Tumor Samples
Osteosarcoma does not respond well to conventional dose methotrexate but does respond to high-dose methotrexate. Previous work has indicated that this resistance may be due to impaired transport of methotrexate across the cell membrane. In this study, the PT430 competitive displacement assay was a...
Main Authors: | Rebecca Sowers, Bethanne D. Wenzel, Condon Richardson, Paul A. Meyers, John H. Healey, Adam S. Levy, Richard Gorlick |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2011-01-01
|
Series: | Sarcoma |
Online Access: | http://dx.doi.org/10.1155/2011/834170 |
Similar Items
-
Patient-derived osteosarcoma cells are resistant to methotrexate.
by: Amanda Dos Santos Cavalcanti, et al.
Published: (2017-01-01) -
Biochemical criteria of toxicity of therapy with high doses of methotrexate in children with osteosarcoma
by: A. M. Strizhevskaya, et al.
Published: (2015-06-01) -
Delayed High-dose Methotrexate Excretion and Influencing Factors in Osteosarcoma Patients
by: Wei Zhang, et al.
Published: (2016-01-01) -
Methotrexate Associated Renal Impairment Is Related to Delayed Elimination of High-Dose Methotrexate
by: Shi-Long Yang, et al.
Published: (2015-01-01) -
Predictors of and variability in methotrexate clearance among osteosarcoma patients receiving high-dose therapy
by: Pinchasik, Dawn
Published: (2013)